Host: Darryl S. Chutka, M.D. [@chutkaMD] Guest: Eric J. Olson, M.D. It’s estimated that about 30 million people in the U.S. have sleep apnea and the worldwide prevalence is approaching 1 billion. The traditional treatment is continuous positive airway pressure or CPAP which is quite effective and used to enhance ventilation. Unfortunately, there are a significant number of patients with sleep apnea who can’t tolerate CPAP. This may result in an untreated patient, increasing their risks to a variety of potentially serious complications. How do we manage the CPAP-intolerant patient? What else is available for the patient with sleep apnea? Which patients are candidates for these alternative treatments and how effective are they? In this podcast, we’ll discuss these questions and more with our guest, sleep expert Eric J. Olson, M.D., from the Division of Pulmonary and Critical Care at the Mayo Clinic. Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Host: Darryl S. Chutka, M.D. [@chutkaMD] Guest: Michael H. Silber, M.B., Ch.B. Depending on the patient, a complaint of feeling tired, fatigued or sleepy may all mean the same thing. In others they may not feel that sleepiness is the same as fatigue or tiredness. Once we sort out what the patient is actually describing, how do we evaluate the sleepy patient? How much sleep do we need per night and what’s an inadequate amount of sleep? How do we evaluate the quality of a patient’s sleep and what role does age play in the evaluation of a patient’s sleep? These are questions we’ll discuss with our guest for this podcast, Michael H. Silber, M.B., Ch.B., a neurologist and sleep expert at the Mayo Clinic. Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Host: Darryl S. Chutka, M.D. [@chutkaMD] Guest: Michael D. Leise, M.D. The liver is the second-most transplanted organ; nearly 10,000 patients received a liver transplant in 2021. The major factor, which has limited the transplants performed, has been the availability of the donated organs and some patients have waited several years before an acceptable organ becomes available. Transplants can be performed for a variety of end-stage liver diseases, usually giving patients years of additional life. Who’s a candidate for a liver transplant and what criteria for selection are required? Our topic for this podcast is “Liver Transplant Selection Criteria” and we’ll discuss this topic with our guest, Michael D. Leise, M.D., from the Division of Gastroenterology and Hepatology at the Mayo Clinic. Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Dr. Samy M. Riad, an expert in kidney transplants and post-transplant care, discusses the unique medical needs of transplant patients, the transition of care for kidney transplant recipients, the importance of immunizations, managing cardiovascular risk factors, and key points about post-transplant care for kidney transplant patients.

Host: Darryl S. Chutka, M.D. [@chutkaMD] Guest: Scott M. Cheney, M.D. Except for skin cancer, prostate cancer is the most common malignancy in males. 1 in 8 men will be diagnosed with prostate cancer during his lifetime, most over the age of 65. If diagnosed early, treatment is quite effective and results in a very favorable survival rate. Several very effective treatment options are now available for patients. In this podcast, we’ll discuss the various treatments and what patients can expect following each option. We’ll review how a post-prostate cancer patient should be followed by their primary care provider and when there might be reason for concern of a recurrence. The guest for this podcast is Scott M. Cheney, M.D., a urologist from the Mayo Clinic in Phoenix, Arizona. This episode is brought to you by: Astellas Oncology | https://astellasoncology.com/ Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Host: Darryl S. Chutka, M.D. [@chutkaMD] Guest: Alan H. Bryce, M.D. Prostate cancer is the second most common malignancy in men, second only to skin cancer and due to increased efforts in screening, most prostate cancers are found very early, and these men have an excellent survival rate. Unfortunately, a percentage of men develop an advanced prostate cancer and the disease becomes much more aggressive with significantly lower survival rates. Who’s at risk for advanced prostate cancer? How does the survival rate change with metastatic disease? Finally, what are the various treatment options and how effective are they? In this podcast, we’ll discuss these questions with our guest, Alan H. Bryce, M.D., from the Division of Hematology and Oncology at the Mayo Clinic. This episode is brought to you by: Astellas Oncology | https://astellasoncology.com/ Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Host: Darryl S. Chutka, M.D. [@chutkaMD] Guest: Nahid Punjani, M.D., M.P.H. Issues related to the prostate can play a significant role in a man’s sexual function. We commonly use medications for benign prostate problems such as BPH which can produce adverse effects. It’s also very common for the treatment of prostate cancer, whether we use radiation therapy, surgical prostatectomy, or hormonal therapy to cause sexual dysfunction. In this podcast, we’ll review the important role the prostate plays in sexual function as we discuss the “Prostate and Sexual Health” with our guest, Nahid Punjani, M.D., M.P.H., a urologist at the Mayo Clinic. This episode is brought to you by: Astellas Oncology | https://astellasoncology.com/ Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Host: Darryl S. Chutka, M.D. [@chutkaMD] Guest: R. Jeffrey Karnes, M.D. Prostate cancer is the most common solid organ malignancy in males, and it’s estimated that 1 in 8 men will develop prostate cancer during their lifetime.  When diagnosed early, it has an excellent survival rate with a variety of very effective treatment options. What are the advantages and disadvantages of each?  Why would one option be chosen over another and how do the adverse effects of the various treatments differ? In this podcast, I’ll be discussing these questions with our guest, R. Jeffrey Karnes, M.D., a urologist at the Mayo Clinic. This episode is brought to you by: Astellas Oncology | https://astellasoncology.com/ Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Host: Darryl S. Chutka, M.D. [@chutkaMD] Guest: Daniel M. Frendl, M.D., Ph.D. Prostate cancer is one of the most common malignancies in men, second only to skin cancer. It’s estimated that 1 in 8 men will develop prostate cancer during their lifetime. The predominant screening test for prostate cancer has been the prostate specific antigen or PSA.  However, there has been some controversy surrounding the use of PSA. It’s an easily administered test, it’s relatively inexpensive and it’s capable of identifying men with possible prostate cancer. So, what’s the controversy? Is the PSA an effective screening test? Who should be tested and how have urologists modified their practice to manage patients with an elevated PSA? We’ll discuss these questions in today’s podcast on “Screening for Prostate Cancer” with our guest, Daniel M. Frendl, M.D., Ph.D., a urologist at the Mayo Clinic. This episode is brought to you by: Astellas Oncology | https://astellasoncology.com/ Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.   

Host: Darryl S. Chutka, M.D. [@chutkaMD] Guest: Mitchell R. Humphreys, M.D. Benign prostatic hyperplasia or BPH is quite common in middle-age and older men. It’s estimated that up to 70% of men over age 60 have symptoms from BPH. While BPH is not a life-threatening condition, it does produce symptoms which can negatively affect the lifestyle of our patients. Since most of the patients with BPH are managed by primary care providers, we should be comfortable with the variety of treatment options available. When should treatment be initiated? What’s available pharmacologically? And when should a urologist be consulted to consider a surgical option? In this podcast, we’ll discuss these questions and more with Mitchell R. Humphreys, M.D., from the Department of Urology at the Mayo Clinic.  This episode is brought to you by: Astellas Oncology | https://astellasoncology.com/ Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.